A next-generation STING agonist MSA-2: From mechanism to application DOI

Junhan Yang,

Zhenyu Luo,

Jingyi Ma

и другие.

Journal of Controlled Release, Год журнала: 2024, Номер 371, С. 273 - 287

Опубликована: Июнь 1, 2024

Язык: Английский

Engineering the Deformability of Albumin‐Stabilized Emulsions for Lymph‐Node Vaccine Delivery DOI
Tiantian Song, Yufei Xia, Yiqun Du

и другие.

Advanced Materials, Год журнала: 2021, Номер 33(26)

Опубликована: Май 19, 2021

Abstract A major challenge in vaccine delivery is to achieve robust lymph‐node (LN) accumulation, which can capitalize on concentrated immunocytes and cytokines LNs stimulate the onset persistence of adaptive immune responses. Previous attempts at developing systems have focused sizes, charges, or surface ligands but not their deformability. In fact, LN homing antigen‐presenting cells depends deformability pass through cellular gaps. Herein, albumin‐stabilized emulsions engineered. Owing self‐adaptive deformability, droplets (≈330 nm) attach deform between adjust sizes endothelial gaps (20–100 nm), favoring direct transfer (intercellular pathway). Additionally, owing relatively large some be retained administration sites for potent antigen uptake activation APCs as well LN‐targeted vaccines (intracellular Compared with solid particles, dual strategy evidently enhances accumulation drainage, potently stimulates responses, increases survival rate tumor‐bearing mice. Thus, may offer an efficient targeting enhanced vaccinations.

Язык: Английский

Процитировано

71

Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy DOI Creative Commons
Lei Lei, Dennis Huang, Huile Gao

и другие.

Science Advances, Год журнала: 2022, Номер 8(47)

Опубликована: Ноя. 23, 2022

Cancer vaccines have attracted widespread interest in tumor therapy because of the potential to induce an effective antitumor immune response. However, many challenges including weak immunogenicity, off-target effects, and immunosuppressive microenvironments prevented their broad clinical translation. To overcome these difficulties, delivery systems been designed for cancer vaccines. As carriers vaccine systems, hydrogels gained substantial attention they can encapsulate a variety antigens/immunomodulators protect them from degradation. This enables simultaneously reverse immunosuppression stimulate Meanwhile, controlled release properties allow precise temporal spatial loads situ further enhance response Therefore, this review summarizes classification vaccines, highlights strategies hydrogel-based provides some insights into future development

Язык: Английский

Процитировано

66

Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine** DOI Open Access
Sonia Jangra,

Jana De Vrieze,

Angela Choi

и другие.

Angewandte Chemie International Edition, Год журнала: 2021, Номер 60(17), С. 9467 - 9473

Опубликована: Янв. 19, 2021

Abstract The search for vaccines that protect from severe morbidity and mortality because of infection with acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus causes disease 2019 (COVID‐19) is a race against clock virus. Here we describe an amphiphilic imidazoquinoline (IMDQ‐PEG‐CHOL) TLR7/8 adjuvant, consisting conjugated to chain end cholesterol‐poly(ethylene glycol) macromolecular amphiphile. It water‐soluble exhibits massive translocation lymph nodes upon local administration through binding albumin, affording localized innate immune activation reduction in systemic inflammation. adjuvanticity IMDQ‐PEG‐CHOL was validated licensed vaccine setting (quadrivalent influenza vaccine) experimental trimeric recombinant SARS‐CoV‐2 spike protein vaccine, showing robust IgG2a IgG1 antibody titers mice could neutralize viral vitro vivo mouse model.

Язык: Английский

Процитировано

63

Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity DOI

Yudi Xu,

Sheng Ma, Jiayu Zhao

и другие.

Biomaterials, Год журнала: 2022, Номер 284, С. 121489 - 121489

Опубликована: Март 25, 2022

Язык: Английский

Процитировано

60

Targeting Lymphatics for Nanoparticle Drug Delivery DOI Creative Commons
Jacob McCright,

Ritika Naiknavare,

Jenny Yarmovsky

и другие.

Frontiers in Pharmacology, Год журнала: 2022, Номер 13

Опубликована: Июнь 3, 2022

The lymphatics transport material from peripheral tissues to lymph nodes, where immune responses are formed, before being transported into systemic circulation. With key roles in and fluid homeostasis, lymphatic dysregulation is linked diseases, including lymphedema. Fluid within the interstitium passes initial vessels a valve system prevents backflow. Additionally, endothelial cells produce chemokines, such as CCL21, that direct migration of dendritic lymphocytes. As result, an attractive delivery route for transporting modulatory treatments nodes immunotherapies potentiated addition alternative method reaching In this review, we discuss physiology mechanisms used materials nodes. We then summarize nanomaterial-based strategies take advantage functions delivering therapeutics or also describe opportunities targeting modulate functions.

Язык: Английский

Процитировано

47

Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy DOI Creative Commons
Ao He, Xiaoye Li, Zhuo Dai

и другие.

Journal of Nanobiotechnology, Год журнала: 2023, Номер 21(1)

Опубликована: Июль 23, 2023

Abstract Therapeutic tumor vaccines have attracted considerable attention in the past decade; they can induce regression, eradicate minimal residual disease, establish lasting immune memory and avoid non-specific adverse side effects. However, challenge field of therapeutic is ensuring delivery components to lymph nodes (LNs) activate cells. The clinical response rate traditional falls short expectations due inadequate node delivery. With rapid development nanotechnology, a large number nanoplatform-based LN-targeting nanovaccines been exploited for optimizing immunotherapies. In addition, some possess non-invasive visualization performance, which benefit understanding kinetics nanovaccine exposure LNs. Herein, we present parameters nanoplatforms, such as size, surface modification, shape, deformability, affect functions nanovaccines. recent advances nanoplatforms with different promoting are also summarized. Furthermore, emerging LNs-targeting nanoplatform-mediated imaging strategies both improve targeting performance enhance quality LN discussed. Finally, summarize prospects challenges /or strategies, optimize efficacy

Язык: Английский

Процитировано

32

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV DOI Creative Commons
Cong Sun, Yinfeng Kang,

Xin‐Yan Fang

и другие.

Cell Host & Microbe, Год журнала: 2023, Номер 31(11), С. 1882 - 1897.e10

Опубликована: Окт. 16, 2023

Язык: Английский

Процитировано

30

Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy DOI
Jingwen Jiang, Yanjuan Huang,

Zishan Zeng

и другие.

ACS Nano, Год журнала: 2023, Номер 17(2), С. 843 - 884

Опубликована: Янв. 4, 2023

Immunotherapy continues to be in the spotlight of oncology therapy research past few years and has been proven a promising option modulate one's innate adaptive immune systems for cancer treatment. However, poor delivery efficiency agents, potential off-target toxicity, nonimmunogenic tumors significantly limit its effectiveness extensive application. Recently, emerging biomaterial-based drug carriers, including but not limited cells bacteria, are expected candidates break dilemma immunotherapy, with their excellent natures intrinsic tumor tropism immunomodulatory activity. More than that, tiny vesicles physiological components derived from them have similar functions source due inheritance various surface signal molecules proteins. Herein, we presented representative examples about latest advances employed cells, derivatives. Simultaneously, opportunities challenges bacteria-based carriers discussed provide reference future application immunotherapy.

Язык: Английский

Процитировано

28

Immunologically effective poly(D-lactic acid) nanoparticle enhances anticancer immune response DOI
Weiguo Xu, Yuanzhen Su, Yang Ma

и другие.

Science China Chemistry, Год журнала: 2023, Номер 66(4), С. 1150 - 1160

Опубликована: Фев. 24, 2023

Язык: Английский

Процитировано

27

Supramolecular Biomaterials for Cancer Immunotherapy DOI Creative Commons

Huan Liang,

Qingqing Lu,

Jie Yang

и другие.

Research, Год журнала: 2023, Номер 6

Опубликована: Янв. 1, 2023

Cancer immunotherapy has achieved tremendous successful clinical results and obtained historic victories in tumor treatments. However, great limitations associated with feeble immune responses serious adverse effects still cannot be neglected due to the complicated multifactorial etiology pathologic microenvironment tumors. The rapid development of nanomedical science material facilitated advanced progress engineering biomaterials tackle critical issues. supramolecular flexible modular structures have exhibited unparalleled advantages high cargo-loading efficiency, excellent biocompatibility, diversiform immunomodulatory activity, thereby providing a powerful weapon for cancer immunotherapy. In past decades, were extensively explored as versatile delivery platforms immunotherapeutic agents or designed interact key moleculars system precise controllable manner. this review, we focused on crucial role modulation pivotal steps during immunotherapy, including antigen presentation, T lymphocyte activation, tumor-associated macrophage elimination repolarization, myeloid-derived suppressor cell depletion. Based extensive research, current prospects

Язык: Английский

Процитировано

27